Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RARA | P10276 | 6/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.38 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 7/20 | 0.35 |
| ▸ | RARB | P10826 | 4/20 | 0.35 |
| ▸ | RARG | P13631 | 4/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.35 |
| ▸ | RXRB | P28702 | 2/20 | 0.35 |
| ▸ | RXRG | P48443 | 2/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1594905 | 1.00 | CYP1A2 (0.50) | CYP1A2MAPTALDH1A1SMN1; SMN2RARA | |
| SCHEMBL1594293 | 0.87 | CYP26A1 (0.41) | CYP1A2MAPTALDH1A1SMN1; SMN2RARA | |
| SCHEMBL1594296 | 0.87 | CYP26A1 (0.41) | CYP1A2MAPTALDH1A1SMN1; SMN2RARA | |
| SCHEMBL954532 | 0.81 | MAPT (0.65) | CYP1A2MAPTALDH1A1SMN1; SMN2RARA | |
| SCHEMBL954530 | 0.81 | MAPT (0.65) | CYP1A2MAPTALDH1A1SMN1; SMN2RARA | |
| SCHEMBL4619550 | 0.81 | CYP1A2 (0.44) | CYP1A2MAPTALDH1A1SMN1; SMN2RARA | |
| SCHEMBL4619546 | 0.81 | CYP1A2 (0.44) | CYP1A2MAPTALDH1A1SMN1; SMN2RARA | |
| SCHEMBL8975623 | 0.78 | MAPT (0.58) | MAPTALDH1A1SMN1; SMN2RARACYP26A1 | |
| SCHEMBL960365 | 0.78 | CYP1A2 (0.51) | CYP1A2MAPTALDH1A1SMN1; SMN2RARA | |
| SCHEMBL956142 | 0.75 | MAPT (0.43) | CYP1A2MAPTALDH1A1SMN1; SMN2RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919624-B2 | VR1 vanilloid receptor antagonists with a iononic substructure | PHARMESTE S.R.L. (IT) | 2011-04-05 | — | — | US | disclosed |
| EP-2046752-B1 | VR1 VANILLOID RECEPTOR ANTAGONISTS WITH A IONONIC SUBSTRUCTURE | PHARMESTE SRL (IT) | 2010-05-19 | — | — | EP | disclosed |
| US-20100035923-A1 | VR1 VANILLOID RECEPTOR ANTAGONISTS WITH A IONONIC SUBSTRUCTURE | PHARMESTE S.R.L. (IT) | 2010-02-11 | — | — | US | disclosed |
| EP-2046752-A1 | VR1 VANILLOID RECEPTOR ANTAGONISTS WITH A IONONIC SUBSTRUCTURE | Pharmeste S.r.l. (IT) | 2009-04-15 | — | — | EP | disclosed |
| EP-1889837-A1 | VR1 vanilloid receptor antagonists with a iononic substructure | Pharmeste S.r.l. (IT) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008006481-A1 | VR1 VANILLOID RECEPTOR ANTAGONISTS WITH A IONONIC SUBSTRUCTURE | PHARMESTE S.R.L. (IT) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035923-A1 | VR1 VANILLOID RECEPTOR ANTAGONISTS WITH A IONONIC SUBSTRUCTURE | TRPV1, TRPV6, TRPV2 | CYP1A2 1074/4885MAPT 4168/4885ALDH1A1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.